Onxeo to Attend Key Investor and Scientific Conferences
Paris (France), January 11, 2021 – 7:00 am CET - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that its management team will attend the following key investor and scientific conferences in the coming months:
- C. Wainwright BioConnect 2021 Conference
January 11-14, 2021 (virtual conference)
For more information and to register, click here
- Biomed Event
January 26-27, 2021 (virtual conference)
For more information and to register, click here
- 4TH Annual PARP & DDR Inhibitors Summit
January 26-28, 2021 (virtual conference)
For more information, click here
- Edison Open House Global Healthcare 2021
January 26-28 2021 (virtual conference)
For more information and to register, click here
- AACR Annual Meeting 2021
April 9-14, 2021 (virtual conference)
For more information and to register, click here
* Given the evolving epidemic context, the reader is invited to refer to the organizers’ websites for possible updates to the conditions of participation.